Literature DB >> 18595776

Hyperbaric oxygen treatment attenuates the pro-inflammatory and immune responses in apolipoprotein E knockout mice.

Bhalchandra Kudchodkar1, Harlan Jones, Jerry Simecka, Ladislav Dory.   

Abstract

Chronic hyperbaric oxygen (HBO) therapy significantly attenuates atherosclerosis in New Zealand white rabbits as well as the apoE knockout (KO) mice, independent of plasma lipid concentrations and lipoprotein profiles. Because atherosclerosis has many features of a chronic inflammatory disease, in which both cell-mediated and humoral immune responses participate, we examined the effect of HBO treatment on various aspects of the immune response. We now demonstrate that in apoE KO mice, HBO treatment significantly reduces the circulating levels of antibodies to (MDA)LDL, both in the IgG and IgM class, as well as the delayed-type hypersensitivity (DTH) response to oxLDL challenge. Furthermore, HBO treatment results in a profound attenuation in the production of pro-inflammatory cytokines in response to an inflammatory stimulus (LPS), which is accompanied by a marked increase in the constitutive production of the anti-inflammatory cytokine IL-10 by spleen cells, independent of antigen specificity, as indicated by polyclonal activation of T cells. Our results demonstrate that HBO treatment results in the dampening of T and B cell-mediated responses to oxLDL or inflammatory stimuli.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18595776      PMCID: PMC2562533          DOI: 10.1016/j.clim.2008.05.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  32 in total

1.  Hyperbaric oxygen treatment reduces carrageenan-induced acute inflammation in rats.

Authors:  G Sümen; M Cimşit; L Eroglu
Journal:  Eur J Pharmacol       Date:  2001-11-16       Impact factor: 4.432

Review 2.  Innate and adaptive immunity in the pathogenesis of atherosclerosis.

Authors:  Göran K Hansson; Peter Libby; Uwe Schönbeck; Zhong-Qun Yan
Journal:  Circ Res       Date:  2002-08-23       Impact factor: 17.367

3.  Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB x NZW) F1 mice.

Authors:  Shao-Yuan Chen; Yen-Chen Chen; Jehng-Kang Wang; Hsiao-Ping Hsu; Pey-Shen Ho; Yi-Chyan Chen; Huey-Kang Sytwu
Journal:  Clin Immunol       Date:  2003-08       Impact factor: 3.969

4.  Tolerance and contact sensitivity to DNFB in mice. I. In vivo detection by ear swelling and correlation with in vitro cell stimulation.

Authors:  P Phanuphak; J W Moorhead; H N Claman
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

5.  The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation.

Authors:  H P Jones; L M Hodge; K Fujihashi; H Kiyono; J R McGhee; J W Simecka
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

6.  Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance.

Authors:  A H Enk; V L Angeloni; M C Udey; S I Katz
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

7.  Suppressive effect of hyperbaric oxygenation on immune responses of normal and autoimmune mice.

Authors:  K Saito; Y Tanaka; T Ota; S Eto; U Yamashita
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

8.  Immunosuppression by hyperbaric oxygen.

Authors:  J F Hansbrough; J G Piacentine; B Eiseman
Journal:  Surgery       Date:  1980-06       Impact factor: 3.982

9.  Oxygen immunosuppression: modification of experimental allergic encephalomyelitis in rodents.

Authors:  J Warren; M R Sacksteder; C A Thuning
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

10.  Immunotoxic potential of antiviral drugs: effects of ganciclovir and (S)-1-(3-hydroxy-2-phosphonylmethoxy propyl) cytosine on lymphocyte transformation and delayed-type hypersensitivity responses.

Authors:  J W Simecka; P Patel; E R Kern
Journal:  Antiviral Res       Date:  1992-05       Impact factor: 5.970

View more
  7 in total

1.  Hyperbaric oxygen ameliorates worsening signs and symptoms of post-traumatic stress disorder.

Authors:  Benjamin Eovaldi; Claude Zanetti
Journal:  Neuropsychiatr Dis Treat       Date:  2010-12-06       Impact factor: 2.570

2.  Osteoclastic resorptive capacity is suppressed in patients receiving hyperbaric oxygen therapy.

Authors:  Hadil Al Hadi; Gary Smerdon; Simon W Fox
Journal:  Acta Orthop       Date:  2014-09-19       Impact factor: 3.717

3.  Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function.

Authors:  Hyung-Ran Kim; Anbok Lee; Eun-Jeong Choi; Min-Pyo Hong; Jeong-Hae Kie; Woosung Lim; Hyeon Kook Lee; Byung-In Moon; Ju-Young Seoh
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

4.  Hyperoxygenation attenuated a murine model of atopic dermatitis through raising skin level of ROS.

Authors:  Hyung-Ran Kim; Jung-Hwan Kim; Eun-Jeong Choi; Yeo Kyong Lee; Jeong-Hae Kie; Myoung Ho Jang; Ju-Young Seoh
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

Review 5.  The Cardiovascular and Metabolic Effects of Chronic Hypoxia in Animal Models: A Mini-Review.

Authors:  Laura A Barnes; Omar A Mesarwi; Ana Sanchez-Azofra
Journal:  Front Physiol       Date:  2022-03-31       Impact factor: 4.566

6.  Anti-Inflammatory Effects of Hyperbaric Oxygenation during DSS-Induced Colitis in BALB/c Mice Include Changes in Gene Expression of HIF-1α, Proinflammatory Cytokines, and Antioxidative Enzymes.

Authors:  Sanja Novak; Ines Drenjancevic; Rosemary Vukovic; Zoltán Kellermayer; Anita Cosic; Maja Tolusic Levak; Péter Balogh; Filip Culo; Martina Mihalj
Journal:  Mediators Inflamm       Date:  2016-08-30       Impact factor: 4.711

7.  Systematic review with meta-analysis: effectiveness of hyperbaric oxygenation therapy for ulcerative colitis.

Authors:  Pingrun Chen; Yina Li; Xian Zhang; Yan Zhang
Journal:  Therap Adv Gastroenterol       Date:  2021-07-17       Impact factor: 4.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.